FENC

insider transactions

FENNEC PHARMACEUTICALS INC. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-70.6K

0 buy · 70.6K sell

Net value · 365d

-$534.3K

$0 in · $534.3K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 70.6K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 10, 26

Khalid Islam

Director

$217.5K

25.0K sh · $8.70

Own +11%
Grant·A
Jun 10, 26

Chris A Rallis

Director

$174.0K

20.0K sh · $8.70

Own +11%
Grant·A
Jun 10, 26

Jodi A Cook

Director

$174.0K

20.0K sh · $8.70

Own +14%
Grant·A
Jun 10, 26

Marco Maria Brughera

Director

$174.0K

20.0K sh · $8.70

Own +9%
Exercise·M
Jun 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
Jun 1, 26

Rosty Raykov

Director · 10b5-1

$93.8K

9.7K sh · $9.62

Own -7%
Exercise·M
Jun 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +13%
Grant·A
May 31, 26

Pierre Sargis Sayad

Chief Medical Officer

$0

168 sh

Own +1%
Grant·A
May 31, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

1.2K sh

Own +2%
Grant·A
May 31, 26

Terry L Evans

Chief Commercial Officer

$0

168 sh

Own +1%
Grant·A
May 31, 26

Christiana Marie Cioffi

Chief Strategy Officer

$0

156 sh

Own +1%
Grant·A
May 31, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

1.7K sh

Own +1%
Grant·A
May 31, 26

Rosty Raykov

Director · 10b5-1

$0

2.8K sh

Own +2%
Exercise·M
May 11, 26

Chris A Rallis

Director · 10b5-1

$35.0K

14.3K sh · $2.44

Own +8%
Sell·S
May 11, 26

Chris A Rallis

Director · 10b5-1

$58.8K

8.3K sh · $7.04

Own -12%
Exercise·M
May 11, 26

Chris A Rallis

Director · 10b5-1

$35.0K

14.3K sh · $2.44

Own +25%
Exercise·M
May 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
May 1, 26

Rosty Raykov

Director · 10b5-1

$69.8K

10.8K sh · $6.47

Own -8%
Exercise·M
May 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +13%
Exercise·M
Apr 30, 26

Pierre Sargis Sayad

Chief Medical Officer

$0

168 sh

Own +1%
Exercise·M
Apr 30, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

1.2K sh

Own +2%
Exercise·M
Apr 30, 26

Rosty Raykov

Director · 10b5-1

$0

2.8K sh

Own +2%
Exercise·M
Apr 30, 26

Terry L Evans

Chief Commercial Officer

$0

168 sh

Own +1%
Exercise·M
Apr 30, 26

Christiana Marie Cioffi

Chief Strategy Officer

$0

155 sh

Own +1%
Exercise·M
Apr 30, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

1.7K sh

Own +1%
Exercise·M
Apr 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
Apr 1, 26

Rosty Raykov

Director · 10b5-1

$69.1K

10.9K sh · $6.31

Own -9%
Exercise·M
Apr 1, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +14%
Grant·A
Mar 31, 26

Pierre Sargis Sayad

Chief Medical Officer

$692.4K

120.0K sh · $5.77

Own +80%
Exercise·M
Mar 31, 26

Pierre Sargis Sayad

Chief Medical Officer

$0

171 sh

Own +1%
Exercise·M
Mar 31, 26

Pierre Sargis Sayad

Chief Medical Officer

$0

18.5K sh

Own New
Grant·A
Mar 31, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$1.2M

200.0K sh · $5.77

Own +38%
Exercise·M
Mar 31, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

1.2K sh

Own +3%
Exercise·M
Mar 31, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

16.7K sh

Own +58%
Grant·A
Mar 31, 26

Rosty Raykov

Director · 10b5-1

$0

5.2K sh

Own +5%
Grant·A
Mar 31, 26

Terry L Evans

Chief Commercial Officer

$692.4K

120.0K sh · $5.77

Own +80%
Exercise·M
Mar 31, 26

Terry L Evans

Chief Commercial Officer

$0

171 sh

Own +1%
Exercise·M
Mar 31, 26

Terry L Evans

Chief Commercial Officer

$0

18.5K sh

Own New
Grant·A
Mar 31, 26

Christiana Marie Cioffi

Chief Strategy Officer

$692.4K

120.0K sh · $5.77

Own +83%
Exercise·M
Mar 31, 26

Christiana Marie Cioffi

Chief Strategy Officer

$0

158 sh

Own +1%
Exercise·M
Mar 31, 26

Christiana Marie Cioffi

Chief Strategy Officer

$0

17.1K sh

Own +364%
Grant·A
Mar 31, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$692.4K

120.0K sh · $5.77

Own +15%
Exercise·M
Mar 31, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

2.2K sh

Own +1%
Exercise·M
Mar 31, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

14.7K sh

Own +6%
Exercise·M
Mar 28, 26

Pierre Sargis Sayad

Chief Medical Officer

$0

2.1K sh

Own +11%
Exercise·M
Mar 28, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

13.9K sh

Own +30%
Exercise·M
Mar 28, 26

Terry L Evans

Chief Commercial Officer

$0

2.1K sh

Own +11%
Exercise·M
Mar 28, 26

Christiana Marie Cioffi

Chief Strategy Officer

$0

1.9K sh

Own +9%
Exercise·M
Mar 28, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

12.3K sh

Own +4%
Exercise·M
Mar 26, 26

Christiana Marie Cioffi

Chief Strategy Officer

$19.9K

4.7K sh · $4.23

Own +3%
Exercise·M
Mar 26, 26

Christiana Marie Cioffi

Chief Strategy Officer

$19.9K

4.7K sh · $4.23

Own New
Exercise·M
Mar 26, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$66.7K

13.1K sh · $5.10

Own +2%
Exercise·M
Mar 26, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$66.7K

13.1K sh · $5.10

Own +5%
Exercise·M
Mar 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
Mar 2, 26

Rosty Raykov

Director · 10b5-1

$84.3K

10.1K sh · $8.36

Own -9%
Exercise·M
Mar 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +16%
Grant·A
Feb 28, 26

Rosty Raykov

Director · 10b5-1

$0

5.2K sh

Own +5%
Grant·A
Feb 28, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

1.2K sh

Own +0%
Exercise·M
Feb 18, 26

Jeffrey S. Hackman KEY

Chief Executive Officer

$0

13.7K sh

Own +91%
Exercise·M
Feb 18, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$10.0K

2.5K sh · $4.08

Own +0%
Exercise·M
Feb 18, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

27.3K sh

Own +13%
Exercise·M
Feb 18, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$10.0K

2.5K sh · $4.08

Own +1%
Exercise·M
Feb 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
Feb 2, 26

Rosty Raykov

Director · 10b5-1

$80.3K

10.3K sh · $7.76

Own -10%
Exercise·M
Feb 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +17%
Grant·A
Jan 31, 26

Rosty Raykov

Director

$0

5.2K sh

Own +6%
Grant·A
Jan 31, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

1.6K sh

Own +1%
Exercise·M
Jan 23, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$24.5K

10.0K sh · $2.45

Own +1%
Exercise·M
Jan 23, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$24.5K

10.0K sh · $2.45

Own +5%
Exercise·M
Jan 15, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$24.5K

10.0K sh · $2.45

Own +1%
Exercise·M
Jan 15, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$24.5K

10.0K sh · $2.45

Own +5%
Exercise·M
Jan 7, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$34.8K

14.2K sh · $2.45

Own +2%
Exercise·M
Jan 7, 26

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$34.8K

14.2K sh · $2.45

Own +8%
Exercise·M
Jan 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +1%
Sell·S
Jan 2, 26

Rosty Raykov

Director · 10b5-1

$78.4K

10.3K sh · $7.60

Own -10%
Exercise·M
Jan 2, 26

Rosty Raykov

Director · 10b5-1

$38.2K

15.6K sh · $2.45

Own +19%
Grant·A
Dec 31, 25

Rosty Raykov

Director · 10b5-1

$0

5.2K sh

Own +7%
Grant·A
Dec 31, 25

Robert Andrade KEY

CHIEF FINANCIAL OFFICER

$0

1.4K sh

Own +1%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 10, 2026	Khalid Islam	Director	Grant A	25.0K	+11%	$8.70	$217.5K
Jun 10, 2026	Chris A Rallis	Director	Grant A	20.0K	+11%	$8.70	$174.0K
Jun 10, 2026	Jodi A Cook	Director	Grant A	20.0K	+14%	$8.70	$174.0K
Jun 10, 2026	Marco Maria Brughera	Director	Grant A	20.0K	+9%	$8.70	$174.0K
Jun 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
Jun 1, 2026	Rosty Raykov 10b5-1	Director	Sell S	9.7K	-7%	$9.62	$93.8K
Jun 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+13%	$2.45	$38.2K
May 31, 2026	Pierre Sargis Sayad	Chief Medical Officer	Grant A	168	+1%	—	$0
May 31, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Grant A	1.2K	+2%	—	$0
May 31, 2026	Terry L Evans	Chief Commercial Officer	Grant A	168	+1%	—	$0
May 31, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Grant A	156	+1%	—	$0
May 31, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Grant A	1.7K	+1%	—	$0
May 31, 2026	Rosty Raykov 10b5-1	Director	Grant A	2.8K	+2%	—	$0
May 11, 2026	Chris A Rallis 10b5-1	Director	Exercise M	14.3K	+8%	$2.44	$35.0K
May 11, 2026	Chris A Rallis 10b5-1	Director	Sell S	8.3K	-12%	$7.04	$58.8K
May 11, 2026	Chris A Rallis 10b5-1	Director	Exercise M	14.3K	+25%	$2.44	$35.0K
May 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
May 1, 2026	Rosty Raykov 10b5-1	Director	Sell S	10.8K	-8%	$6.47	$69.8K
May 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+13%	$2.45	$38.2K
Apr 30, 2026	Pierre Sargis Sayad	Chief Medical Officer	Exercise M	168	+1%	—	$0
Apr 30, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Exercise M	1.2K	+2%	—	$0
Apr 30, 2026	Rosty Raykov 10b5-1	Director	Exercise M	2.8K	+2%	—	$0
Apr 30, 2026	Terry L Evans	Chief Commercial Officer	Exercise M	168	+1%	—	$0
Apr 30, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	155	+1%	—	$0
Apr 30, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	1.7K	+1%	—	$0
Apr 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
Apr 1, 2026	Rosty Raykov 10b5-1	Director	Sell S	10.9K	-9%	$6.31	$69.1K
Apr 1, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+14%	$2.45	$38.2K
Mar 31, 2026	Pierre Sargis Sayad	Chief Medical Officer	Grant A	120.0K	+80%	$5.77	$692.4K
Mar 31, 2026	Pierre Sargis Sayad	Chief Medical Officer	Exercise M	171	+1%	—	$0
Mar 31, 2026	Pierre Sargis Sayad	Chief Medical Officer	Exercise M	18.5K	New	—	$0
Mar 31, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Grant A	200.0K	+38%	$5.77	$1.2M
Mar 31, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Exercise M	1.2K	+3%	—	$0
Mar 31, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Exercise M	16.7K	+58%	—	$0
Mar 31, 2026	Rosty Raykov 10b5-1	Director	Grant A	5.2K	+5%	—	$0
Mar 31, 2026	Terry L Evans	Chief Commercial Officer	Grant A	120.0K	+80%	$5.77	$692.4K
Mar 31, 2026	Terry L Evans	Chief Commercial Officer	Exercise M	171	+1%	—	$0
Mar 31, 2026	Terry L Evans	Chief Commercial Officer	Exercise M	18.5K	New	—	$0
Mar 31, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Grant A	120.0K	+83%	$5.77	$692.4K
Mar 31, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	158	+1%	—	$0
Mar 31, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	17.1K	+364%	—	$0
Mar 31, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Grant A	120.0K	+15%	$5.77	$692.4K
Mar 31, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	2.2K	+1%	—	$0
Mar 31, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	14.7K	+6%	—	$0
Mar 28, 2026	Pierre Sargis Sayad	Chief Medical Officer	Exercise M	2.1K	+11%	—	$0
Mar 28, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Exercise M	13.9K	+30%	—	$0
Mar 28, 2026	Terry L Evans	Chief Commercial Officer	Exercise M	2.1K	+11%	—	$0
Mar 28, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	1.9K	+9%	—	$0
Mar 28, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	12.3K	+4%	—	$0
Mar 26, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	4.7K	+3%	$4.23	$19.9K
Mar 26, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Exercise M	4.7K	New	$4.23	$19.9K
Mar 26, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	13.1K	+2%	$5.10	$66.7K
Mar 26, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	13.1K	+5%	$5.10	$66.7K
Mar 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
Mar 2, 2026	Rosty Raykov 10b5-1	Director	Sell S	10.1K	-9%	$8.36	$84.3K
Mar 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+16%	$2.45	$38.2K
Feb 28, 2026	Rosty Raykov 10b5-1	Director	Grant A	5.2K	+5%	—	$0
Feb 28, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Grant A	1.2K	+0%	—	$0
Feb 18, 2026	Jeffrey S. Hackman KEY	Chief Executive Officer	Exercise M	13.7K	+91%	—	$0
Feb 18, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	2.5K	+0%	$4.08	$10.0K
Feb 18, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	27.3K	+13%	—	$0
Feb 18, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	2.5K	+1%	$4.08	$10.0K
Feb 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
Feb 2, 2026	Rosty Raykov 10b5-1	Director	Sell S	10.3K	-10%	$7.76	$80.3K
Feb 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+17%	$2.45	$38.2K
Jan 31, 2026	Rosty Raykov	Director	Grant A	5.2K	+6%	—	$0
Jan 31, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Grant A	1.6K	+1%	—	$0
Jan 23, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	10.0K	+1%	$2.45	$24.5K
Jan 23, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	10.0K	+5%	$2.45	$24.5K
Jan 15, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	10.0K	+1%	$2.45	$24.5K
Jan 15, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	10.0K	+5%	$2.45	$24.5K
Jan 7, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	14.2K	+2%	$2.45	$34.8K
Jan 7, 2026	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Exercise M	14.2K	+8%	$2.45	$34.8K
Jan 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+1%	$2.45	$38.2K
Jan 2, 2026	Rosty Raykov 10b5-1	Director	Sell S	10.3K	-10%	$7.60	$78.4K
Jan 2, 2026	Rosty Raykov 10b5-1	Director	Exercise M	15.6K	+19%	$2.45	$38.2K
Dec 31, 2025	Rosty Raykov 10b5-1	Director	Grant A	5.2K	+7%	—	$0
Dec 31, 2025	Robert Andrade KEY	CHIEF FINANCIAL OFFICER	Grant A	1.4K	+1%	—	$0

About FENC insider trading

This page tracks insider transactions for FENNEC PHARMACEUTICALS INC. (FENC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.